BACKGROUND: Differentiating treatment-induced injury from recurrent high-grade glioma is an ongoing challenge in neuro-oncology, in part due to lesion heterogeneity. This study aimed to determine whether different MR features were relevant for distinguishing recurrent tumor from the effects of treatment in contrast-enhancing lesions (CEL) and non-enhancing lesions (NEL). METHODS: This prospective study analyzed 291 tissue samples (222 recurrent tumor, 69 treatment-effect) with known coordinates on imaging from 139 patients who underwent preoperative 3T MRI and surgery for a suspected recurrence. 8 MR parameter values were tested from perfusion-weighted, diffusion-weighted, and MR spectroscopic imaging at each tissue sample location for association with histopathological outcome using generalized estimating equation models for CEL and NEL tissue samples. Individual cutoff values were evaluated using receiver operating characteristic curve analysis with 5-fold cross-validation. RESULTS: In tissue samples obtained from CEL, elevated relative cerebral blood volume (rCBV) was associated with the presence of recurrent tumor pathology (P < 0.03), while increases in normalized choline (nCho) and choline-to-NAA index (CNI) were associated with the presence of recurrent tumor pathology in NEL tissue samples (P < 0.008). A mean CNI cutoff value of 2.7 had the highest performance, resulting in mean sensitivity and specificity of 0.61 and 0.81 for distinguishing treatment-effect from recurrent tumor within the NEL. CONCLUSION: Although our results support prior work that underscores the utility of rCBV in distinguishing the effects of treatment from recurrent tumor within the contrast enhancing lesion, we found that metabolic parameters may be better at differentiating recurrent tumor from treatment-related changes in the NEL of high-grade gliomas.
BACKGROUND: Differentiating treatment-induced injury from recurrent high-grade glioma is an ongoing challenge in neuro-oncology, in part due to lesion heterogeneity. This study aimed to determine whether different MR features were relevant for distinguishing recurrent tumor from the effects of treatment in contrast-enhancing lesions (CEL) and non-enhancing lesions (NEL). METHODS: This prospective study analyzed 291 tissue samples (222 recurrent tumor, 69 treatment-effect) with known coordinates on imaging from 139 patients who underwent preoperative 3T MRI and surgery for a suspected recurrence. 8 MR parameter values were tested from perfusion-weighted, diffusion-weighted, and MR spectroscopic imaging at each tissue sample location for association with histopathological outcome using generalized estimating equation models for CEL and NEL tissue samples. Individual cutoff values were evaluated using receiver operating characteristic curve analysis with 5-fold cross-validation. RESULTS: In tissue samples obtained from CEL, elevated relative cerebral blood volume (rCBV) was associated with the presence of recurrent tumor pathology (P < 0.03), while increases in normalized choline (nCho) and choline-to-NAA index (CNI) were associated with the presence of recurrent tumor pathology in NEL tissue samples (P < 0.008). A mean CNI cutoff value of 2.7 had the highest performance, resulting in mean sensitivity and specificity of 0.61 and 0.81 for distinguishing treatment-effect from recurrent tumor within the NEL. CONCLUSION: Although our results support prior work that underscores the utility of rCBV in distinguishing the effects of treatment from recurrent tumor within the contrast enhancing lesion, we found that metabolic parameters may be better at differentiating recurrent tumor from treatment-related changes in the NEL of high-grade gliomas.
Authors: Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544
Authors: Augusto E Elias; Ruth C Carlos; Ethan A Smith; Dan Frechtling; Bekris George; Pavel Maly; Pia C Sundgren Journal: Acad Radiol Date: 2011-09 Impact factor: 3.173
Authors: Ilwoo Park; Albert P Chen; Matthew L Zierhut; Esin Ozturk-Isik; Daniel B Vigneron; Sarah J Nelson Journal: Ann Biomed Eng Date: 2010-07-23 Impact factor: 3.934
Authors: R Jain; J Narang; L Schultz; L Scarpace; S Saksena; S Brown; J P Rock; M Rosenblum; J Gutierrez; T Mikkelsen Journal: AJNR Am J Neuroradiol Date: 2011-02-17 Impact factor: 3.825
Authors: Jack P Rock; David Hearshen; Lisa Scarpace; David Croteau; Jorge Gutierrez; James L Fisher; Mark L Rosenblum; Tom Mikkelsen Journal: Neurosurgery Date: 2002-10 Impact factor: 4.654
Authors: Abdul W Abbasi; Henriette E Westerlaan; Gea A Holtman; Kamal M Aden; Peter Jan van Laar; Anouk van der Hoorn Journal: Clin Neuroradiol Date: 2017-05-02 Impact factor: 3.649
Authors: Tomas Kazda; Martin Bulik; Petr Pospisil; Radek Lakomy; Martin Smrcka; Pavel Slampa; Radim Jancalek Journal: Neuroimage Clin Date: 2016-02-26 Impact factor: 4.881
Authors: Thomas C Booth; Mariusz Grzeda; Alysha Chelliah; Andrei Roman; Ayisha Al Busaidi; Carmen Dragos; Haris Shuaib; Aysha Luis; Ayesha Mirchandani; Burcu Alparslan; Nina Mansoor; Jose Lavrador; Francesco Vergani; Keyoumars Ashkan; Marc Modat; Sebastien Ourselin Journal: Front Oncol Date: 2022-01-31 Impact factor: 6.244